A detailed history of Principal Financial Group Inc transactions in Sana Biotechnology, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 12,364 shares of SANA stock, worth $32,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,364
Previous 25,781 52.04%
Holding current value
$32,270
Previous $140,000 63.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$3.76 - $6.86 $50,447 - $92,040
-13,417 Reduced 52.04%
12,364 $51,000
Q2 2024

Jul 29, 2024

SELL
$5.23 - $10.44 $55,505 - $110,799
-10,613 Reduced 29.16%
25,781 $140,000
Q1 2024

Apr 29, 2024

SELL
$4.2 - $11.27 $11,902 - $31,939
-2,834 Reduced 7.22%
36,394 $363,000
Q4 2023

Feb 07, 2024

SELL
$2.8 - $4.55 $9,620 - $15,633
-3,436 Reduced 8.05%
39,228 $160,000
Q3 2023

Nov 02, 2023

BUY
$3.77 - $6.23 $18,578 - $30,701
4,928 Added 13.06%
42,664 $165,000
Q2 2023

Aug 07, 2023

SELL
$3.22 - $7.53 $331 - $775
-103 Reduced 0.27%
37,736 $224,000
Q1 2023

May 09, 2023

BUY
$3.11 - $4.92 $7,146 - $11,306
2,298 Added 6.47%
37,839 $123,000
Q4 2022

Feb 09, 2023

BUY
$3.19 - $6.46 $14,370 - $29,102
4,505 Added 14.52%
35,541 $140,000
Q3 2022

Nov 09, 2022

BUY
$5.58 - $9.04 $28,976 - $46,944
5,193 Added 20.09%
31,036 $186,000
Q2 2022

Aug 10, 2022

SELL
$4.12 - $9.35 $44,726 - $101,503
-10,856 Reduced 29.58%
25,843 $166,000
Q1 2022

May 09, 2022

SELL
$5.24 - $15.58 $707 - $2,103
-135 Reduced 0.37%
36,699 $304,000
Q4 2021

Feb 09, 2022

BUY
$15.18 - $23.15 $293,201 - $447,142
19,315 Added 110.25%
36,834 $571,000
Q3 2021

Nov 09, 2021

BUY
$16.29 - $25.88 $285,384 - $453,391
17,519 New
17,519 $395,000

Others Institutions Holding SANA

About Sana Biotechnology, Inc.


  • Ticker SANA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 190,232,000
  • Market Cap $497M
  • Description
  • Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...
More about SANA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.